$TNGX
Tango Therapeutics, Inc.

2023 Q2 Form 10-Q Financial Statement

#000095017023019140 Filed on May 09, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q1
Revenue $14.60M $5.766M $5.758M
YoY Change 152.95% 0.14% -9.83%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $9.174M $8.013M $6.807M
YoY Change 26.85% 17.72% 2459.98%
% of Gross Profit
Research & Development $28.67M $28.04M $24.33M
YoY Change 20.77% 15.24% 62.2%
% of Gross Profit
Depreciation & Amortization $604.0K $600.0K $300.0K
YoY Change 93.59% 100.0% 50.0%
% of Gross Profit
Operating Expenses $37.85M $36.05M $31.14M
YoY Change 22.19% 15.79% 68.61%
Operating Profit -$23.25M -$30.29M -$25.38M
YoY Change -7.76% 19.33% 110.07%
Interest Expense $1.450M $1.061M $218.0K
YoY Change 388.22% 386.7% 717.4%
% of Operating Profit
Other Income/Expense, Net $2.601M $2.278M $171.0K
YoY Change 5102.0% 1232.16% 248.98%
Pretax Income -$20.65M -$28.01M -$25.21M
YoY Change -16.93% 11.11% 109.51%
Income Tax $64.00K $0.00 $0.00
% Of Pretax Income
Net Earnings -$20.71M -$28.01M -$25.21M
YoY Change -16.69% 11.11% 108.23%
Net Earnings / Revenue -141.87% -485.74% -437.79%
Basic Earnings Per Share -$0.23 -$0.32 -$0.29
Diluted Earnings Per Share -$0.23 -$0.32 -$287.5K
COMMON SHARES
Basic Shares Outstanding 88.41M 88.20M 87.71M
Diluted Shares Outstanding 88.35M 88.19M 87.67M

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $310.7M $333.6M $449.9M
YoY Change -25.39% -25.84% 35648.85%
Cash & Equivalents $66.05M $57.25M $99.91M
Short-Term Investments $244.6M $276.4M $350.0M
Other Short-Term Assets $9.891M $9.361M $8.769M
YoY Change -44.21% 6.75% 4447.53%
Inventory
Prepaid Expenses
Receivables $0.00 $0.00 $2.000M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $320.5M $343.0M $460.7M
YoY Change -26.5% -25.54% 31641.22%
LONG-TERM ASSETS
Property, Plant & Equipment $10.88M $11.11M $6.538M
YoY Change 22.55% 69.87%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $12.00K $19.00K $16.00K
YoY Change -99.65% 18.75%
Total Long-Term Assets $58.79M $60.77M $10.87M
YoY Change 377.38% 459.04% -93.48%
TOTAL ASSETS
Total Short-Term Assets $320.5M $343.0M $460.7M
Total Long-Term Assets $58.79M $60.77M $10.87M
Total Assets $379.3M $403.8M $471.5M
YoY Change -15.4% -14.37% 180.23%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.793M $6.296M $3.367M
YoY Change 183.11% 86.99% 4828.28%
Accrued Expenses $14.99M $13.33M $10.77M
YoY Change 1.37% 23.79% 4659.34%
Deferred Revenue $33.85M $34.01M $25.02M
YoY Change 35.91%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $53.63M $53.67M $39.21M
YoY Change 20.03% 36.88% 12885.49%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $112.8M $122.8M $112.0M
YoY Change 7.37% 9.72% 1818.32%
Total Long-Term Liabilities $112.8M $122.8M $112.0M
YoY Change 7.37% 9.72% 1818.32%
TOTAL LIABILITIES
Total Short-Term Liabilities $53.63M $53.67M $39.21M
Total Long-Term Liabilities $112.8M $122.8M $112.0M
Total Liabilities $166.4M $176.5M $151.2M
YoY Change 11.15% 16.76% 2362.75%
SHAREHOLDERS EQUITY
Retained Earnings -$318.2M -$297.5M -$186.5M
YoY Change 59.49%
Common Stock $88.00K $88.00K $88.00K
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $212.9M $227.3M $320.4M
YoY Change
Total Liabilities & Shareholders Equity $379.3M $403.8M $471.5M
YoY Change -15.4% -14.37% 180.23%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q1
OPERATING ACTIVITIES
Net Income -$20.71M -$28.01M -$25.21M
YoY Change -16.69% 11.11% 108.23%
Depreciation, Depletion And Amortization $604.0K $600.0K $300.0K
YoY Change 93.59% 100.0% 50.0%
Cash From Operating Activities -$24.47M -$34.91M -$29.67M
YoY Change -22.4% 17.67% 117.92%
INVESTING ACTIVITIES
Capital Expenditures $664.0K $620.0K $1.561M
YoY Change -136.66% -60.28% 846.06%
Acquisitions
YoY Change
Other Investing Activities $33.35M $32.17M -$10.16M
YoY Change -10.6% -416.77%
Cash From Investing Activities $32.69M $31.55M -$11.72M
YoY Change -7.91% -369.28% -156.85%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 586.0K 73.00K 257.0K
YoY Change -18.38% -71.6% -99.15%
NET CHANGE
Cash From Operating Activities -24.47M -34.91M -29.67M
Cash From Investing Activities 32.69M 31.55M -11.72M
Cash From Financing Activities 586.0K 73.00K 257.0K
Net Change In Cash 8.800M -3.283M -41.13M
YoY Change 88.32% -92.02% -209.93%
FREE CASH FLOW
Cash From Operating Activities -$24.47M -$34.91M -$29.67M
Capital Expenditures $664.0K $620.0K $1.561M
Free Cash Flow -$25.14M -$35.53M -$31.23M
YoY Change -15.44% 13.77% 126.64%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001819133
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-39485
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
TANGO THERAPEUTICS, INC.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
85-1195036
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
201 Brookline Ave.
CY2023Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 901
CY2023Q1 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Boston
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02215
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2022Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
CY2023Q1 dei City Area Code
CityAreaCode
857
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
320-4900
CY2023Q1 dei Security12b Title
Security12bTitle
Common stock, par value $0.001 per share
CY2023Q1 dei Trading Symbol
TradingSymbol
TNGX
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
88406523
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
57252000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
59968000
CY2023Q1 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
276387000
CY2022Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
306165000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2000000
CY2022Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
567000
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
9361000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6572000
CY2023Q1 us-gaap Assets Current
AssetsCurrent
343000000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
375272000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
11106000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10884000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
46225000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
46886000
CY2023Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
3423000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
3423000
CY2023Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
19000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5000
CY2023Q1 us-gaap Assets
Assets
403773000
CY2022Q4 us-gaap Assets
Assets
436470000
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
6296000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4453000
CY2023Q1 tngx Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
10692000
CY2022Q4 tngx Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
17495000
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2638000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1770000
CY2023Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
34011000
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
31792000
CY2023Q1 us-gaap Taxes Payable Current
TaxesPayableCurrent
35000
CY2022Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
35000
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
53672000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
55545000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
38735000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
39361000
CY2023Q1 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
84102000
CY2022Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
92088000
CY2023Q1 us-gaap Liabilities
Liabilities
176509000
CY2022Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
10000000
CY2023Q1 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0
CY2022Q4 us-gaap Liabilities
Liabilities
186994000
CY2023Q1 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
10000000
CY2023Q1 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
0
CY2022Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0
CY2022Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
0
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
88209964
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
88209964
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
88179374
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
88179374
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
88000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
88000
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
526897000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
522605000
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2201000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-3705000
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-297520000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-269512000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
227264000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
249476000
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
403773000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
436470000
CY2023Q1 us-gaap Revenues
Revenues
5766000
CY2022Q1 us-gaap Revenues
Revenues
5758000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
28039000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
24330000
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8013000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6807000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
36052000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
31137000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-30286000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-25379000
CY2023Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
1061000
CY2022Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
218000
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1217000
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-47000
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2278000
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
171000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-28008000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-25208000
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.32
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.32
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.29
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.29
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
88193917
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
88193917
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
87670653
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1561000
CY2023Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
84705000
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
87670653
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-28008000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-25208000
CY2023Q1 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
1504000
CY2022Q1 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-2645000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-26504000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-27853000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
249476000
CY2023Q1 tngx Stock Issued During Period Value Stock Options And Employee Stock Purchase Plan Exercised
StockIssuedDuringPeriodValueStockOptionsAndEmployeeStockPurchasePlanExercised
73000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
4219000
CY2023Q1 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
1504000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-28008000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
227264000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
344747000
CY2022Q1 tngx Stock Issued During Period Value Stock Options And Employee Stock Purchase Plan Exercised
StockIssuedDuringPeriodValueStockOptionsAndEmployeeStockPurchasePlanExercised
265000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
3205000
CY2022Q1 tngx Adjustments To Additional Paid In Capital Business Combination And Pipe Financing Issuance Costs
AdjustmentsToAdditionalPaidInCapitalBusinessCombinationAndPipeFinancingIssuanceCosts
8000
CY2022Q1 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
-2645000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-25208000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
320356000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-28008000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-25208000
CY2023Q1 us-gaap Depreciation
Depreciation
581000
CY2022Q1 us-gaap Depreciation
Depreciation
309000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
877000
CY2022Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
361000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
4219000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
3205000
CY2023Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
889000
CY2022Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-54000
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-2000000
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2783000
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3687000
CY2023Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
13000
CY2022Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-4000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
1552000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-359000
CY2023Q1 tngx Increase Decrease In Accrued Expenses And Other Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherLiabilities
-6703000
CY2022Q1 tngx Increase Decrease In Accrued Expenses And Other Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherLiabilities
-157000
CY2023Q1 tngx Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
26000
CY2022Q1 tngx Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-429000
CY2023Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-5766000
CY2022Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-3758000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-34907000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-29665000
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
620000
CY2022Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
44415000
CY2023Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
52534000
CY2022Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
54571000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
31551000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-11717000
CY2023Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
73000
CY2022Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
265000
CY2022Q1 tngx Payment Of Business Combination And Pipe Financing Transaction Costs
PaymentOfBusinessCombinationAndPipeFinancingTransactionCosts
8000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
73000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
257000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-3283000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-41125000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
63958000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
145024000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
60675000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
103899000
CY2023Q1 tngx Cash Paid For Leases
CashPaidForLeases
746000
CY2022Q1 tngx Cash Paid For Leases
CashPaidForLeases
465000
CY2023Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
290000
CY2022Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
500000
CY2023Q1 tngx Revaluation Of Right Of Use Asset And Lease Liability Upon Lease Modification
RevaluationOfRightOfUseAssetAndLeaseLiabilityUponLeaseModification
-215000
CY2022Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
236129000
CY2022Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
3726000
CY2023Q1 us-gaap Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss
900000
CY2022Q4 us-gaap Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss
500
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of consolidated financial statements requires that the Company make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. Significant estimates and assumptions made in the consolidated financial statements include, but are not limited to, the revenue recognized from collaboration agreements, the valuation of stock-based awards and the accrual for research and development expenses. On an ongoing basis, the Company evaluates its estimates, judgments and methodologies. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. As of the date of issuance of these consolidated financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update estimates, judgments or revise the carrying value of any assets or liabilities. Actual results may differ from these estimates under different assumptions or conditions. Changes in estimates are reflected in reported results in the period in which they become known.</span></p>
CY2023Q1 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P4Y4M24D
CY2023Q1 tngx Fair Value Asset Level1 To Level2 Transfer Amount
FairValueAssetLevel1ToLevel2TransferAmount
0
CY2023Q1 tngx Fair Value Asset Level2 To Level1 Transfer Amount
FairValueAssetLevel2ToLevel1TransferAmount
0
CY2023Q1 tngx Fair Value Liabilities Level1 To Level2 Transfer Amounts
FairValueLiabilitiesLevel1ToLevel2TransferAmounts
0
CY2023Q1 tngx Fair Value Liabilities Level2 To Level1 Transfer Amounts
FairValueLiabilitiesLevel2ToLevel1TransferAmounts
0
CY2023Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
278595000
CY2023Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
54000
CY2023Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
2262000
CY2023Q1 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
276387000
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
309870000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
21000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
3726000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
306165000
CY2023Q1 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
94820000
CY2023Q1 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
477000
CY2023Q1 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
108055000
CY2023Q1 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
1784000
CY2023Q1 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
202876000
CY2023Q1 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
2262000
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
113132000
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
1267000
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
122997000
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
2459000
CY2023Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
15347000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
14565000
CY2023Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4241000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3681000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
11106000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10884000
CY2023Q1 us-gaap Depreciation
Depreciation
600000
CY2022Q1 us-gaap Depreciation
Depreciation
300000
CY2023Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2040000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5738000
CY2023Q1 tngx Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
7127000
CY2022Q4 tngx Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
10490000
CY2023Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1525000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1267000
CY2023Q1 tngx Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
10692000
CY2022Q4 tngx Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
17495000
CY2023Q1 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
10000000
CY2023Q1 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
0
CY2023Q1 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4219000
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3205000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
12924086
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.50
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y1M17D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
24267448000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
4257952
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
5.37
CY2023Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
30590
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.37
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
133208
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
9.65
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
17018240
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.20
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y4M13D
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
6441051000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
6042026
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
5.32
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y3M3D
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
5253390000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-28008000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-25208000
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
88193917
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
88193917
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
87670653
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
87670653
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.32
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.32
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.29
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.29
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
17651866
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12741946
CY2023Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2022Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q1 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2022Q1 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210

Files In Submission

Name View Source Status
0000950170-23-019140-index-headers.html Edgar Link pending
0000950170-23-019140-index.html Edgar Link pending
0000950170-23-019140.txt Edgar Link pending
0000950170-23-019140-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tngx-20230331.htm Edgar Link pending
tngx-20230331.xsd Edgar Link pending
tngx-ex31_1.htm Edgar Link pending
tngx-ex31_2.htm Edgar Link pending
tngx-ex32_1.htm Edgar Link pending
tngx-ex32_2.htm Edgar Link pending
tngx-20230331_cal.xml Edgar Link unprocessable
tngx-20230331_lab.xml Edgar Link unprocessable
tngx-20230331_def.xml Edgar Link unprocessable
tngx-20230331_pre.xml Edgar Link unprocessable
tngx-20230331_htm.xml Edgar Link completed